Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 05, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | GeoVax Labs, Inc. | |
Entity Central Index Key | 0000832489 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 13,819,101 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Title of 12(g) Security | Common Stock $.001 par value |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
ASSETS | ||
Cash and cash equivalents | $ 221,807 | $ 283,341 |
Grant funds and other receivables | 520,509 | 68,603 |
Prepaid expenses and other current assets | 67,895 | 95,320 |
Total current assets | 810,211 | 447,264 |
Property and equipment, net (Note 5) | 9,612 | 10,606 |
Deposits | 11,010 | 11,010 |
Total assets | 830,833 | 468,880 |
Current liabilities: | ||
Accounts payable | 740,829 | 152,653 |
Accrued expenses (Note 6) | 1,917,425 | 1,851,040 |
Current portion of notes payable (Note 7) | 12,048 | 12,500 |
Total current liabilities | 2,670,302 | 2,016,193 |
Note payable, net of current portion (Note 7) | 24,781 | 27,243 |
Total liabilities | 2,695,083 | 2,043,436 |
Commitments (Note 8) | ||
Stockholders’ equity (deficiency): | ||
Preferred Stock, $.01 par value (Note 9): Authorized shares – 10,000,000 Issued and outstanding shares – 400 and 2,486 March 31, 2020 and December 31, 2019, respectively | 376,095 | 1,932,433 |
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 13,791,601 and 299,835 at March 31, 2020 and December 31, 2019, respectively | 13,792 | 300 |
Additional paid-in capital | 41,189,070 | 39,340,224 |
Accumulated deficit | (43,443,207) | (42,847,513) |
Total stockholders’ equity (deficiency) | (1,864,250) | (1,574,556) |
Total liabilities and stockholders’ equity (deficiency) | $ 830,833 | $ 468,880 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 400 | 2,486 |
Preferred stock, shares outstanding (in shares) | 400 | 2,486 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 13,791,601 | 299,835 |
Common stock, shares outstanding (in shares) | 13,791,601 | 299,835 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Grant and collaboration revenues | $ 715,977 | $ 364,232 |
Operating expenses: | ||
Research and development | 808,936 | 555,718 |
General and administrative | 502,345 | 510,064 |
Total operating expenses | 1,311,281 | 1,065,782 |
Loss from operations | (595,304) | (701,550) |
Other income (expense): | ||
Interest income | 752 | 1,224 |
Interest expense | (1,142) | (1,128) |
Total other income (expense) | (390) | 96 |
Net loss | $ (595,694) | $ (701,454) |
Basic and diluted: | ||
Net loss per common share (in dollars per share) | $ (0.13) | $ (2,851.44) |
Weighted average shares outstanding (in shares) | 4,687,893 | 246 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 3,450 | 219 | |||
Balance at Dec. 31, 2018 | $ 1,971,333 | $ 37,483,204 | $ (40,476,884) | $ (1,022,347) | |
Sale of convertible preferred stock for cash (in shares) | 500 | ||||
Sale of convertible preferred stock for cash | $ 404,250 | 85,750 | 490,000 | ||
Conversion of preferred stock to common stock (in shares) | (767) | 59 | |||
Conversion of preferred stock to common stock | $ (303,475) | 303,475 | |||
Net loss | (701,454) | (701,454) | |||
Stock-based compensation expense | 26,652 | 26,652 | |||
Balance (in shares) at Mar. 31, 2019 | 3,183 | 278 | |||
Balance at Mar. 31, 2019 | $ 2,072,108 | 37,899,081 | (41,178,338) | (1,207,149) | |
Balance (in shares) at Dec. 31, 2019 | 2,486 | 299,835 | |||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 300 | 39,340,224 | (42,847,513) | (1,574,556) |
Sale of convertible preferred stock for cash (in shares) | 300 | ||||
Sale of convertible preferred stock for cash | $ 300,000 | 300,000 | |||
Conversion of preferred stock to common stock (in shares) | (2,386) | 13,481,349 | |||
Conversion of preferred stock to common stock | $ (1,856,338) | $ 13,481 | 1,842,857 | ||
Issuance of common stock for services (in shares) | 10,417 | 10,417 | |||
Issuance of common stock for services | $ 11 | 5,989 | $ 6,000 | ||
Net loss | (595,694) | (595,694) | |||
Balance (in shares) at Mar. 31, 2020 | 400 | 13,791,601 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 13,792 | $ 41,189,070 | $ (43,443,207) | $ (1,864,250) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (595,694) | $ (701,454) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 994 | 1,897 |
Stock-based compensation expense | 6,000 | 153,224 |
Changes in assets and liabilities: | ||
Grant funds and other receivables | (451,906) | (38,463) |
Prepaid expenses and other current assets | 27,425 | (30) |
Accounts payable and accrued expenses | 654,561 | 267,465 |
Total adjustments | 237,074 | 384,093 |
Net cash used in operating activities | (358,620) | (317,361) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (4,272) | |
Net cash used in investing activities | (4,272) | |
Cash flows from financing activities: | ||
Net proceeds from sale of preferred stock | 300,000 | 240,000 |
Principal repayment of note payable | (2,914) | (2,083) |
Net cash provided by financing activities | 297,086 | 237,917 |
Net increase (decrease) in cash and cash equivalents | (61,534) | (83,716) |
Cash and cash equivalents at beginning of period | 283,341 | 259,701 |
Cash and cash equivalents at end of period | $ 221,807 | $ 175,985 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) | 3 Months Ended |
Mar. 31, 2019USD ($)shares | |
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member] | |
Convertible preferred stock (in shares) | 1,563 |
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member] | |
Convertible preferred stock (in shares) | 1,200 |
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member] | |
Conversion of stock, shares issued (in shares) | 2,763 |
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member] | |
Convertible preferred stock (in shares) | 250 |
Convertible note, value | $ | $ 250,000 |
Conversion of Series C Preferred Stock Into Common Stock [Member] | |
Convertible preferred stock (in shares) | 587 |
Conversion of stock, shares issued (in shares) | 39 |
Conversion of Series F Preferred Stock Into Common Stock [Member] | |
Convertible preferred stock (in shares) | 180 |
Conversion of stock, shares issued (in shares) | 20 |
Note 1 - Description of Busines
Note 1 - Description of Business | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) vaccine platform (GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to improve the health of patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We intend to advance products through to human clinical testing, and to seek partnership or licensing arrangements for commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | 2. The accompanying condensed consolidated financial statements at March 31, 2020 three March 31, 2020 2019 not 10 December 31, 2019. not As described in Note 9, April 30, 2019, one five hundred January 21, 2020, one two thousand Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources together with our government and collaborative funding commitments, will be sufficient to continue our planned operations into the third 2020. not may not |
Note 3 - Significant Accounting
Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. We disclosed in Note 2 10 December 31, 2019 no 10 There have been no three March 31, 2020, 10 December 31, 2019, |
Note 4 - Basic and Diluted Loss
Note 4 - Basic and Diluted Loss Per Common Share | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 970,571 295 March 31, 2020 2019, 9 March 31, 2020 |
Note 5 - Property and Equipment
Note 5 - Property and Equipment | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (652,306 ) (651,312 ) Property and equipment, net $ 9,612 $ 10,606 |
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020 December 31, 2019 Accrued management salaries $ 1,418,797 $ 1,323,483 Accrued directors’ fees 436,920 409,219 Other accrued expenses 61,708 118,338 Total accrued expenses $ 1,917,425 $ 1,851,040 |
Note 7 - Notes Payable
Note 7 - Notes Payable | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 7. On February 28, 2018, five $50,000. 5%, $8,964 2020 $12,487 2021, $13,126 2022, $2,252 2023. three March 31, 2020 2019 $485 $621, |
Note 8 - Commitments
Note 8 - Commitments | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Commitments Disclosure [Text Block] | 8. Lease Agreement We lease approximately 8,400 December 31, 2022. three March 31, 2020 2019 $41,539 $40,316, $124,616 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of March 31, 2020, $539,000 2020. |
Note 9 - Stockholders' Equity
Note 9 - Stockholders' Equity | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 9. Preferred Stock Summary 10,000,000 $.01 may one March 31, 2020 December 31, 2019. $1,000 three March 31, 2020 March 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433 Series B Preferred Stock -- no not March 31, 2020, 100 $350,000 no three March 31, 2020. Series H Preferred Stock – no not three March 31, 2020, 1,686 9,393,937 March 31, 2020, no Series I Preferred Stock – no not three March 31, 2020, 700 4,087,412 March 31, 2020, no Series J Preferred Stock – January 24, 2020, 300 $300,000. no not $2.00 80% ten may, three March 31, 2020, no 300 March 31, 2020. Common Stock Reverse Stock Split – January 3, 2020, January 21, 2020, one two thousand As discussed under “Preferred Stock” above, during the three March 31, 2020, 13,481,349 During the three March 31, 2020, 10,417 $6,000 Stock Options During the three March 31, 2020, no April 2019 January 2020, March 31, 2020 no three March 31, 2020. Stock Purchase Warrants The following table summarizes our stock purchase warrants outstanding as of March 31, 2020: Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48 All of the outstanding warrants contain anti-dilution and price adjustment provisions, which may, no April 30, 2019 January 21, 2020 Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $- 0 $26,652 three March 31, 2020 2019, March 31, 2020, no Additionally, during the three March 31, 2020 2019 $6,000 $126,572, |
Note 10 - Income Taxes
Note 10 - Income Taxes | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 10. Because of our historically significant net operating losses, we have not 382 |
Note 11 - Grants and Collaborat
Note 11 - Grants and Collaboration Revenue | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Government Grants and Contracts [Text Block] | 11. We receive payments from government entities under grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three March 31, 2020 2019, $654,021 $354,319, March 31, 2020, $606,944 2020. During the three March 31, 2020 2019, $61,956 $9,913, third |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 12. CARES Act Paycheck Protection Program Loan On April 17, 2020, $170,200 one April 17, 2022. No 180 November 17, 2020, $9,578.16 may may |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | March 31, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (652,306 ) (651,312 ) Property and equipment, net $ 9,612 $ 10,606 |
Note 6 - Accrued Expenses (Tabl
Note 6 - Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | March 31, 2020 December 31, 2019 Accrued management salaries $ 1,418,797 $ 1,323,483 Accrued directors’ fees 436,920 409,219 Other accrued expenses 61,708 118,338 Total accrued expenses $ 1,917,425 $ 1,851,040 |
Note 9 - Stockholders' Equity (
Note 9 - Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Preferred Stock [Table Text Block] | March 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48 |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation (Details Textual) | Jan. 21, 2020 | Apr. 30, 2019 |
Reverse Stock Split [Member] | ||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 2,000 | 500 |
Note 4 - Basic and Diluted Lo_2
Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 970,571 | 295 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Property and equipment, gross | $ 661,918 | $ 661,918 |
Accumulated depreciation and amortization | (652,306) | (651,312) |
Property and equipment, net | 9,612 | 10,606 |
Laboratory Equipment [Member] | ||
Property and equipment, gross | 534,577 | 534,577 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 115,605 | 115,605 |
Other Furniture Fixtures And Equipment [Member] | ||
Property and equipment, gross | $ 11,736 | $ 11,736 |
Note 6 - Accrued Expenses - Sch
Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Accrued management salaries | $ 1,418,797 | $ 1,323,483 |
Accrued directors’ fees | 436,920 | 409,219 |
Other accrued expenses | 61,708 | 118,338 |
Total accrued expenses | $ 1,917,425 | $ 1,851,040 |
Note 7 - Notes Payable (Details
Note 7 - Notes Payable (Details Textual) - USD ($) | Feb. 28, 2018 | Mar. 31, 2020 | Mar. 31, 2019 |
Interest Expense, Total | $ 1,142 | $ 1,128 | |
Senior Notes [Member] | |||
Proceeds from Notes Payable, Total | $ 50,000 | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||
Long-Term Debt, Maturity, Remainder of Fiscal Year | 8,964 | ||
Long-Term Debt, Maturity, Year Two | 12,487 | ||
Long-Term Debt, Maturity, Year Three | 13,126 | ||
Long-Term Debt, Maturity, Year Four | 2,252 | ||
Interest Expense, Total | $ 485 | $ 621 |
Note 8 - Commitments (Details T
Note 8 - Commitments (Details Textual) | 3 Months Ended | |
Mar. 31, 2020USD ($)ft² | Mar. 31, 2019USD ($) | |
Area of Real Estate Property (Square Foot) | ft² | 8,400 | |
Operating Leases, Rent Expense, Total | $ 41,539 | $ 40,316 |
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | 124,616 | |
Lessee, Operating Lease, Liability, Payments, Due Year Two | 171,213 | |
Lessee, Operating Lease, Liability, Payments, Due Year Three | 176,356 | |
Unrecorded Unconditional Purchase Obligation, Total | $ 539,000 |
Note 9 - Stockholders' Equity_2
Note 9 - Stockholders' Equity (Details Textual) | Jan. 24, 2020USD ($)$ / sharesshares | Jan. 21, 2020 | Apr. 30, 2019 | Mar. 31, 2020USD ($)$ / sharesshares | Mar. 31, 2019USD ($) | Dec. 31, 2019$ / sharesshares |
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | ||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | ||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 400 | 2,486 | ||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 10,417 | |||||
Stock Issued During Period, Value, Issued for Services | $ | $ 6,000 | |||||
Conversion of Stock, Shares Converted | $ | 0 | |||||
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $ | 6,000 | $ 126,572 | ||||
Share-based Payment Arrangement, Option [Member] | ||||||
Share-based Payment Arrangement, Expense | $ | $ 0 | $ 26,652 | ||||
Reverse Stock Split [Member] | ||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 2,000 | 500 | ||||
Conversion of Series H Preferred Stock Into Common Stock [Member] | ||||||
Conversion of Stock, Shares Converted (in shares) | 1,686 | |||||
Conversion of Stock, Shares Issued (in shares) | 9,393,937 | |||||
Conversion of Series I Preferred Stock Into Common Stock [Member] | ||||||
Conversion of Stock, Shares Converted (in shares) | 700 | |||||
Conversion of Stock, Shares Issued (in shares) | 4,087,412 | |||||
Conversion of Series H and Series I Preferred Stock Into Common Stock [Member] | ||||||
Conversion of Stock, Shares Issued (in shares) | 13,481,349 | |||||
Series B Convertible Preferred Stock [Member] | ||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 1,000 | |||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 100 | 100 | ||||
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares | $ 350,000 | |||||
Series H Convertible Preferred Stock [Member] | ||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 1,686 | ||||
Series I Convertible Preferred Stock [Member] | ||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 700 | ||||
Series J Convertible Preferred Stock [Member] | ||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 300 | |||||
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares | $ 2 | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 300 | |||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ | $ 300,000 |
Note 9 - Stockholders' Equity -
Note 9 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Preferred stock, shares outstanding (in shares) | 400 | 2,486 |
Preferred Stock | $ 376,095 | $ 1,932,433 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 100 | 100 |
Preferred Stock | $ 76,095 | $ 76,095 |
Series H Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 0 | 1,686 |
Preferred Stock | $ 1,156,338 | |
Series I Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 0 | 700 |
Preferred Stock | $ 700,000 | |
Series J Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 300 | |
Preferred Stock | $ 300,000 |
Note 9 - Stockholders' Equity_3
Note 9 - Stockholders' Equity - Summary of Warrants (Details) | Mar. 31, 2020$ / sharesshares |
Series G Warrants [Member] | |
Exercise price (in dollars per share) | $ / shares | $ 25,440 |
Number of warrants (in shares) | shares | 48 |
Series H Warrants [Member] | |
Exercise price (in dollars per share) | $ / shares | $ 1.15 |
Number of warrants (in shares) | shares | 217,392 |
Series I Warrants [Member] | |
Exercise price (in dollars per share) | $ / shares | $ 15,000 |
Number of warrants (in shares) | shares | 48 |
Note 10 - Income Taxes (Details
Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Income Taxes Paid | $ 0 | $ 0 |
Note 11 - Grants and Collabor_2
Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 715,977 | $ 364,232 |
Unused Grant Funds | 606,944 | |
NIH Grants [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | 654,021 | 354,319 |
Research Agreements [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | $ 61,956 | $ 9,913 |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] | Apr. 17, 2020USD ($) |
Proceeds From Paycheck Protection Program Under CARES Act | $ 170,200 |
Paycheck Protection Program Loan [Member] | |
Debt Instrument, Periodic Payment, Total | $ 9,578.16 |